Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy
$900m Upfront
Executive Summary
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.
You may also be interested in...
AstraZeneca Expands Lymphoma Pipeline With TeneoTwo Acquisition
AstraZeneca has bought TeneoTwo and its bispecific asset TNB-486 to enlarge its hemato-oncology pipeline but the UK major is still a long way off being a key player in the field.
Amgen Rebuilt R&D Platform To Focus On Speed And Access
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.